GIP and type 2 diabetes mellitus: In the current study, we here determined active GIP, GLP-1, and glucagon levels in type 2 diabetes mellitus (T2DM) subjects with or without DPP-4 inhibitor treatment to characterize the cell-based, receptor-mediated bioassays in comparison to immunoassays.